Accordingly, the K14-HPV16 transgenic mice develop epidermal hyperplasia that progresses to dysplasia and in situ carcinoma (CIS) lesions and, ultimately, to invasive cancer. The gene discussed is KRT14; the disease is in situ carcinoma.